Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could CT scans replace MRI for cervical cancer radiation? major study launches

NCT ID NCT07249021

Knowledge-focused Sponsor: Homi Bhabha Cancer Hospital & Research Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether using CT scans instead of MRI for planning brachytherapy (internal radiation) can work just as well for locally advanced cervical cancer. About 1,200 participants will receive standard treatment, and researchers will track tumor control and side effects. The goal is to make high-quality brachytherapy more available in places where MRI is not easily accessible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include approximately 1200 women with histologically confirmed, locally advanced cervical cancer (FIGO stages IB3-IVA) who are planned for curative chemoradiation followed by brachytherapy at the primary treating center. Participants will be recruited from multiple national and international centres equipped with CT-based brachytherapy facilities. All will undergo standardized treatment and follow-up as per study protocol, with imaging and outcome data submitted to a centralized database for quality assurance and analysis.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Cancer of the uterine cervix considered suitable for curative treatment with definitive chemo radiotherapy including brachytherapy. 2. Biopsy showing invasive squamous-cell carcinoma or adenocarcinoma or adeno - squamous cell carcinoma of the uterine cervix. 3. FIGO (2018) stage IB2 to IVA 4. Willingness to participate by signing informed consent form. Exclusion Criteria: * Other previous or current primary malignancies except carcinoma in situ of the cervix. * Metastatic Inguinal Nodes not amenable to radical radiation therapy * Metastatic disease in para-aortic region beyond renal vessels * Not eligible for concurrent cisplatin chemotherapy (creatinine clearance \< 50mg/ml/min) * Previous pelvic or abdominal radiotherapy. * Previous total or partial hysterectomy. * Patients receiving BT alone. * Patients receiving EBRT alone. * Patients receiving any form of neoadjuvant anti-neoplastic therapy prior to definitive treatment or adjuvant therapy * Active infection or severe medical condition which precludes radical chemoradiotherapy. * Pregnant or lactating or childbearing potential without adequate contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brachytherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brachytherapy CT Locally advanced cervical cancer Transrectal ultrasound

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Homi Bhabha Cancer Hopsital & Research Centre

    Visakhapatnam, Andhra Pradesh, 530053, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.